

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT4629867

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
QUIDEL CARDIOVASCULAR INC.	10/06/2017
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
<b>Street Address:</b>	10623 NE 68TH STREET
<b>Internal Address:</b>	WA3-132-01-01
<b>City:</b>	KIRKLAND
<b>State/Country:</b>	WASHINGTON
<b>Postal Code:</b>	98033
<b>PROPERTY NUMBERS Total: 17</b>	
<b>Property Type</b>	<b>Number</b>
Patent Number:	6074616
Patent Number:	6392894
Patent Number:	6194222
Patent Number:	7713703
Patent Number:	6830731
Patent Number:	7416700
Patent Number:	7588908
Application Number:	14391643
Patent Number:	D639976
Patent Number:	D640389
Patent Number:	D639977
Patent Number:	7713705
Patent Number:	7842472
Patent Number:	7985560
Patent Number:	8283128
Patent Number:	8524462
Patent Number:	8969018
<b>CORRESPONDENCE DATA</b>	

**Fax Number:** (704)444-8857

***Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.***

**Phone:** 7043432000

**Email:** twitcher@mcguirewoods.com

**Correspondent Name:** TERRY L. WITCHER, PARALEGAL

**Address Line 1:** MCGUIREWOODS LLP

**Address Line 2:** 201 N. TRYON STREET, SUITE 3000

**Address Line 4:** CHARLOTTE, NORTH CAROLINA 28202

<b>ATTORNEY DOCKET NUMBER:</b>	2068279-2042
--------------------------------	--------------

<b>NAME OF SUBMITTER:</b>	TERRY L. WITCHER, PARALEGAL
---------------------------	-----------------------------

<b>SIGNATURE:</b>	/s/ Terry L. Witcher
-------------------	----------------------

<b>DATE SIGNED:</b>	10/06/2017
---------------------	------------

**Total Attachments: 5**

source=Patent Security Interest - Quidel Cardiovascular#page1.tif

source=Patent Security Interest - Quidel Cardiovascular#page2.tif

source=Patent Security Interest - Quidel Cardiovascular#page3.tif

source=Patent Security Interest - Quidel Cardiovascular#page4.tif

source=Patent Security Interest - Quidel Cardiovascular#page5.tif

## GRANT OF PATENT SECURITY INTEREST

**WHEREAS, QUIDEL CARDIOVASCULAR INC.**, a Delaware corporation (“Grantor”), owns and uses in its business, and will in the future adopt and so use, various intangible assets, including the Patent Collateral (as defined below); and

**WHEREAS**, Quidel Corporation, a Delaware corporation (“Borrower”), has entered into that certain Credit Agreement dated as of October 6, 2017 (as amended, restated, extended, supplemented or otherwise modified in writing from time to time, the “Credit Agreement”) with the financial institutions named therein (collectively, together with their respective successors and assigns party to the Credit Agreement from time to time, the “Lenders”), and Bank of America, N.A., as Administrative Agent for the Lenders (in such capacity, “Secured Party”) pursuant to which Lenders have made certain commitments, subject to the terms and conditions set forth in the Credit Agreement, to extend certain credit facilities to Borrower; and

**WHEREAS**, any Loan Party (as defined in the Credit Agreement) may from time to time enter, or may from time to time have entered, into one or more swap agreements (collectively, the “Secured Hedge Agreements”) with one or more Persons that are Lenders or Affiliates of Lenders at the time such Secured Hedge Agreements are entered into (in such capacity, collectively, “Hedge Banks”);

**WHEREAS**, any Loan Party (as defined in the Credit Agreement) may from time to time enter, or may from time to time have entered, into one or more cash management agreement (collectively, the “Secured Cash Management Agreements”) with one or more Persons that are Lenders or Affiliates of Lenders at the time such Secured Cash Management Agreements are entered into (in such capacity, collectively, “Cash Management Banks”); and

**WHEREAS**, Grantor has executed and delivered that certain Guaranty Agreement dated as of October 6, 2017 (said Guaranty Agreement, as it may heretofore have been and as it may hereafter be further amended, restated, supplemented or otherwise modified from time to time, the “Guaranty”) in favor of Secured Party for the benefit of Lenders, any Hedge Banks and any Cash Management Banks, pursuant to which Grantor has guaranteed the prompt payment and performance when due of all obligations of Borrower under the Credit Agreement and the other Loan Documents (as defined in the Credit Agreement) and all obligations of Loan Parties (as defined in the Credit Agreement) under the Secured Hedge Agreements and the Secured Cash Management Agreements, including, without limitation, the obligation of Loan Parties to make payments under the Secured Hedge Agreements in the event of early termination thereof; and

**WHEREAS**, pursuant to the terms of that certain Security Agreement dated as of October 6, 2017 (said Security Agreement, as it may heretofore have been and as it may hereafter be further amended, restated, supplemented or otherwise modified from time to time, the “Security Agreement”), among Grantor, Secured Party and the other grantors named therein, Grantor has created in favor of Secured Party a security interest in, and Secured Party has become a secured creditor with respect to, the Patent Collateral;

**NOW, THEREFORE**, for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, subject to the terms and conditions of the Security Agreement, to evidence further the security interest granted by Grantor to Secured Party pursuant to the Security Agreement, Grantor hereby grants to Secured Party a security interest in all of Grantor’s right, title and interest in and to the following, in each case whether now or hereafter existing or in which Grantor now has or hereafter acquires an interest and wherever the same may be located (the “Patent Collateral”) to secure the Secured Obligations (as defined in the Security Agreement):

(i) all rights, title and interest (including rights acquired pursuant to a license or otherwise but only to the extent permitted by agreements governing such license or other use) in and to all patents and patent applications and rights and interests in patents and patent applications under any domestic or foreign law that are presently, or in the future may be, owned or held by such Grantor and all patents and patent applications and rights, title and interests in patents and patent applications under any domestic or foreign law that are presently, or in the future may be, owned by such Grantor in whole or in part (including, without limitation, the patents and patent applications set forth on Schedule A annexed hereto), all rights (but not obligations) corresponding thereto to sue for past, present and future infringements and all re-issues, divisions, continuations, renewals, extensions and continuations-in-part thereof; and

(ii) all proceeds, products, rents and profits of or from any and all of the foregoing Patent Collateral and, to the extent not otherwise included, all payments under insurance (whether or not Secured Party is the loss payee thereof), or any indemnity, warranty or guaranty, payable by reason of loss or damage to or otherwise with respect to any of the foregoing Patent Collateral. For purposes of this Grant of Patent Security Interest, the term "proceeds" includes whatever is receivable or received when Patent Collateral or proceeds are sold, licensed, exchanged, collected or otherwise disposed of, whether such disposition is voluntary or involuntary.

Grantor does hereby further acknowledge and affirm that the rights and remedies of Secured Party with respect to the security interest in the Patent Collateral granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

[The remainder of this page intentionally left blank.]

IN WITNESS WHEREOF, Grantor has caused this Grant of Patent Security Interest to be duly executed and delivered by its officer thereunto duly authorized as of the day of October 6, 2017.

**GRANTOR:**

**QUIDEL CARDIOVASCULAR INC.**

By: Robert Bujanski  
Name: Robert Bujanski  
Title: Secretary

**SCHEDULE A  
TO  
GRANT OF PATENT SECURITY INTEREST**

Title	Serial No.	Filing Date	Grant No.	Country	Status
MEDIA CARRIER FOR AN ASSAY DEVICE	09/003,066	5-Jan-98	6,074,616	United States of America	Granted
MEDIA CARRIER FOR AN ASSAY DEVICE	09/545,699	06-Apr-00	6,392,894	United States of America	Granted
METHODS FOR MONITORING THE STATUS OF ASSAYS AND IMMUNOASSAYS	09/003,065	5-Jan-98	6,194,222	United States of America	Granted
METHODS FOR MONITORING THE STATUS OF ASSAYS AND IMMUNOASSAYS	09/712,615	13-Nov-00	7,713,703	United States of America	Granted
IMMUNOASSAY FLUOROMETER	09/003,090	05-Jan-98	6,830,731	United States of America	Granted
IMMUNOASSAY FLUOROMETER	10/267,232	08-Oct-02	7,416,700	United States of America	Granted
NOVEL COMPOSITIONS AND METHODS FOR INHIBITING LIGHT-INDUCED INACTIVATION OF BIOLOGICAL REAGENTS	10/338,182	07-Jan-03	7,588,908	United States of America	Granted
MICROFLUIDIC DEVICE, SYSTEM AND METHOD	14/391,643	09-Oct-14		United States of America	Pending
TEST STRIP COVER	29/363,034	03-Jun-10	D639,976	United States of America	Granted
TEST STRIP	29/363,033	03-Jun-10	D640,389	United States of America	Granted

Title	Serial No.	Filing Date	Grant No.	Country	Status
TEST STRIP BASE	29/363,035	03-Jun-10	D639,977	United States of America	Granted
MARKERS FOR DIFFERENTIAL DIAGNOSIS AND METHODS OF USE THEREOF	10/330,696	27-Dec-02	7,713,705	United States of America	Granted
METHODS AND COMPOSITIONS FOR MONITORING AND RISK PREDICTION IN CARDIORENAL SYNDROME	11/940,111	14-Nov-07	7,842,472	United States of America	Granted
METHODS AND COMPOSITIONS FOR MONITORING AND RISK PREDICTION IN CARDIORENAL SYNDROME	12/909,654	21-Oct-10	7,985,560	United States of America	Granted
METHODS AND COMPOSITIONS FOR MONITORING AND RISK PREDICTION IN CARDIORENAL SYNDROME	13/152,009	02-Jun-11	8,283,128	United States of America	Granted
METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL ARTERY STENOSIS	12/513,499	08-Dec-09	8,524,462	United States of America	Granted
METHODS AND COMPOSITIONS FOR MONITORING AND RISK PREDICTION IN CARDIORENAL SYNDROME	14/196,346	04-Mar-14	8,969,018	United States of America	Granted

PATENT

REEL: 043803 FRAME: 0365

RECORDED: 10/06/2017